Search
Clidinium
go.drugbank.com/drugs/DB00771ApprovedIt is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome. … Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract.
Aflibercept
go.drugbank.com/drugs/DB08885ApprovedInvestigational[A261281,A261286] Due to the 2 fused VEGFR, aflibercept has a higher affinity to the cognate ligands than the endogenous individual receptor. … However, it lacks the intracellular structure to propagate subsequent signal transduction, thus essentially sequestering the ligands to prevent activation of VEGFR.
Talc
go.drugbank.com/drugs/DB09511ApprovedInvestigationalAlthough talc has been widely used for decades, lawsuits that have come to the surface claim serious health complications linked to its use. … In fact, recent studies have reported that talc increases the risk of ovarian and endometrial cancers by approximately 30 percent.
Lanadelumab
go.drugbank.com/drugs/DB14597ApprovedInvestigational[A38676] Lanadelumab was approved for use in patients with hereditary angioedema by the FDA in August 2018,[L4537] followed by Health Canada in October 2018[L49226] and the EMA in November 2018.
Brexanolone
go.drugbank.com/drugs/DB11859ApprovedInvestigationalAs of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically … PPD whereas many commonly used anti-depressive medications elicit actions that may modulate the presence and activity of substances like serotonin, norepinephrine, and/or monoamine oxidase but do not
Betrixaban
go.drugbank.com/drugs/DB12364ApprovedBetrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks … It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity [A27286].
Pemigatinib
go.drugbank.com/drugs/DB15102ApprovedInvestigationalThis malignancy accounts for 15% to 20% of primary hepatobiliary malignancies, which account for 13% of overall cancer-related global mortality. … growth factor receptor 2 (FGFR2) gene fusion or other rearrangements as detected by an FDA-approved test.
Tolrestat
go.drugbank.com/drugs/DB02383ApprovedWithdrawnIt was sold under the tradename Alredase but was discontinued by Wyeth in 1997 because of the risk of severe liver toxicity and death. … While it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval.
Lasmiditan
go.drugbank.com/drugs/DB11732ApprovedInvestigational[L9338,L9356] It was also approved by the European Commission on August 17, 2022.[L43997] Traditionally, the triptan class of anti-migraine medications (e.g. … [sumatriptan]) have seen preferential use in the acute treatment of migraines due to their relatively favourable efficacy and safety.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeCalcium acetate
go.drugbank.com/drugs/DB00258ApprovedIt has been commonly referred to as the acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form.
Products: PHOS-NO 1000 MG TABLET, 180 ADET